Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

Repros Therapeutics (RPRX +2.5%) moves up after saying that it's conducting a 6-month 500...

  • Monday, February 11, 1:51 PM ET
    Repros Therapeutics (RPRX +2.5%) moves up after saying that it's conducting a 6-month 500 subject open label study as part of an FDA requirement for Androxal, and it's sent a "request for guidance" letter to the agency regarding two other pivotal studies on the drug as well. Additionally, the company also says its requested an end of Phase 2 meeting before the end of April for its vaginal Proellex program for the treatment of uterine fibroids.
Track new comments on this story

This news story has 1 comment:

  •  
    The biggest problem with clomophene citrate (Clomid) is that the cis-isomer form has negative mood effects and lowers libido. Whether the trans isomer (Androxal) does that I have not seen such in the studies so far. What I have seen are the Testosterone (T) values and sperm counts. If anyone has any mood-libido data on Androxal please contact me. I have treated over 300 men with Clomid to determine functionality of pituitary and as a T replacement. About 65% report negative mood-libido despite elevated T levels which some describe as an Estrogenic-like feeling.
    Let me know.
    Karlis Ullis, MD
    kullismd@gmail.com
    http://bit.ly/JdtaAH
    12 Feb, 12:34 AM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »